27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Effective, scalable dementia prevention interventions are needed to address modifiable risk factors given global burden of dementia and challenges in developing disease-modifying treatments. 1 key finding →
Design: randomized controlled trial Participants: 6,104 Evidence: high
Full summary, score breakdown and related studies → Original source
Initially, healthy older adults randomized to speed of processing cognitive training had a 29% reduction in their risk of dementia after 10 years of follow-up compared to the untreated control group. 5 key findings →
Design: randomized controlled trial Participants: 2,802 Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's Disease (AD) is a pathology with increasing prevalence in the context of a more long-lived society and it is the first cause of dementia in western countries. 2 key findings →
Design: systematic review Participants: 12,458 Evidence: high
Full summary, score breakdown and related studies → Original source
An 18-month multimodal intervention for older adults at risk of dementia could improve their cognitive function. 2 key findings →
Design: randomized controlled trial Participants: 203 Evidence: high
Full summary, score breakdown and related studies → Original source
Among cognitively unimpaired participants with a family history of dementia, changes in cognition and brain MRI outcomes from baseline to year 3 did not differ significantly between those who followed the MIND diet and those who followed the control diet with mild caloric restriction. 5 key findings →
Design: RCT Participants: 604 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
In this meta-analysis of randomized clinical trials, blood pressure lowering with antihypertensive agents compared with control was significantly associated with a lower risk of incident dementia or cognitive impairment. 4 key findings →
Design: meta-analysis Participants: 96,158 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. 4 key findings →
Design: randomized controlled trial Participants: 631 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Data collection and analysis We initially screened search results using a 'crowdsourcing' method in which members of Cochrane's citizen science platform identify RCTs. 4 key findings →
Design: meta-analysis Participants: 400 Evidence: high
Full summary, score breakdown and related studies → Original source
The multidomain intervention showed no efficacy in preventing cognitive decline. 2 key findings →
Participants: 531 Evidence: high
Full summary, score breakdown and related studies → Original source
The interventions were positively perceived, with 72.0% finding the consultation informative and 69.2% considering the app useful. 5 key findings →
Design: randomized controlled trial Participants: 188 Evidence: high
Full summary, score breakdown and related studies → Original source
Adults aged 65+ are at highest risk for severe COVID-19 outcomes, and prior to the distribution of vaccines in the U.S., were strongly advised to quarantine at home to reduce risk of infection. 3 key findings →
Design: randomized controlled trial Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source
Greater adherence to a Mediterranean diet is associated with a significant improvement in health status, as seen by a significant reduction in overall mortality (9%), mortality from cardiovascular diseases (9%), incidence of or mortality from cancer (6%), and incidence of Parkinson's disease and Alzheimer's disease (13%). 3 key findings →
Design: meta-analysis Participants: 574,299 Evidence: high
Full summary, score breakdown and related studies → Original source
Further studies are warranted to develop and refine the specific MIND diet for different populations. 4 key findings →
Design: meta-analysis Participants: 224,049 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After a median of 4.7 years of follow-up, the rate of cardiovascular disease was 10.7 events per 1000 person-years in the aspirin group and 11.3 events per 1000 person-years in the placebo group (hazard ratio, 0.95; 95% confidence interval [CI], 0.83 to 1.08). 4 key findings →
Participants: 19,114 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Current pharmacologic therapies are for symptomatic AD patients, whereas nonpharmacologic training is administrable before symptom onset. 1 key finding →
Design: randomized controlled trial Participants: 125 Evidence: high
Full summary, score breakdown and related studies → Original source
There is moderate-certainty evidence regarding the benefit of multicomponent non-pharmacological interventions for the prevention of delirium in hospitalised adults, estimated to reduce incidence by 43% compared to usual care. 4 key findings →
Design: meta-analysis Participants: 22 Evidence: high
Full summary, score breakdown and related studies → Original source
Profiles of high risk for future dementia are well understood and are likely to concern mostly those in low-income and middle-income countries and people at greater disadvantage in high-income countries. 1 key finding →
Design: randomized controlled trial Participants: 2,400 Evidence: high
Full summary, score breakdown and related studies → Original source
The first single-stage individual patient data meta-analysis from randomized double-blind placebo-controlled clinical trials provides evidence to support benefits of antihypertensive treatment in late-mid and later life to lower the risk of dementia. 5 key findings →
Design: meta-analysis Participants: 28,008 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Screening commenced in July 2022. Currently, 1,965 participants have been randomized into lifestyle intervention (n = 772) and control groups (n = 1,193). 5 key findings →
Design: randomized controlled trial Participants: 772 Evidence: high
Full summary, score breakdown and related studies → Original source
Median follow-up by intention to treat was 2.0 years. 2 key findings →
Participants: 1,180 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Main results We included two trials with 26,340 participants aged 40 to 82 years of whom 11,610 were aged 70 or older. 2 key findings →
Design: meta-analysis Participants: 26,340 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The task force issued five statements related to the management of anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adults admitted to the ICU. 5 key findings →
Design: systematic review Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 21,788 citations were screened, and seven studies of diverse quality were included in the review, comprising 1,691 participants. 3 key findings →
Design: systematic review Participants: 1,691 Evidence: high
Full summary, score breakdown and related studies → Original source
Despite older racial and ethnic minorities (REMs) being more likely to develop dementia they are underrepresented in clinical trials focused on neurological disorders. 5 key findings →
Design: systematic review Participants: 100,748 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 45 reviews with 212 meta-analyses were synthesized. 5 key findings →
Design: meta-analysis Participants: 45 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →